Biopharma

#Biopharma #Biotechnology #Collaboration #Life sciences #Technology

Why quantum computing in drug discovery needs to improve  

The Pistoia Alliance has released new results from a survey of 260 attendees from life science companies across the globe, finding that almost half classify their understanding of quantum computing (QC) technology at the beginner level (48%) only. This is followed by intermediate (29%), advanced (13%), and expert at 9%. Read More

#News #Trends & Analysis

#Biopharma #Drug discovery #Life sciences #R&D

Abcam opens new US site

Abcam has opened a new site in Waltham, MA. The facility is a central part of Abcam’s growth in the US and will serve as a hub for its R&D and commercial activities in the region. “Abcam’s first step toward global expansion was in 2003 at Kendall Square.  Since then,… Read More

#News

#AI / data analytics / healthtech / informatics #Big pharma #Biopharma #Biotechnology #Covid-19 #Drug development #Drug discovery

Waters CEO explains how analytical technologies can assist drug discovery

Udit Batra, CEO of Waters, is known as a listener, learner and gatherer of facts. He talks to Lu Rahman about Waters’ collaboration with pharma and biopharma companies to accelerate vaccine and therapy development as well as the company’s new data analysis technology. LR: We know that the last year… Read More

#Exclusive Content #News

#Biopharma #Biotechnology #Covid-19 #Drug discovery #Laboratory data #Life sciences

From siloed to streamlined: Pharma data management is changing

Claire Hill, Head of Strategic Marketing at IDBS, explores ways in which the pharmaceutical sector can reap the benefits of an increasingly digital world. The Covid-19 pandemic pushed the process of drug development into the spotlight in a new way. The challenge for biopharmaceutical companies—to create, test, and manufacture a… Read More

#Exclusive Content #News #Opinion

#Biopharma #Cell and gene therapy

Rentschler Biopharma to build new cell and gene therapy capabilities in the UK

The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre for advancing the UK’s cell and gene therapy industry, and Rentschler Biopharma, a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, have announced that Rentschler Biopharma will establish its manufacturing capability in Advanced Therapy Medicinal Products (ATMPs), including… Read More

#Editor's Choice #News

#Biopharma #Drug development #Drug discovery

Thermo Fisher Scientific extends collaboration to advance biopharma discovery

Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody centre of excellence within the international pharmaceutical company, Servier, have extended a collaboration to deliver innovative characterisation and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development. Since the collaboration was… Read More

#News

#Antibodies #Biologics / Biotechnology #Biopharma

Bristol Myers Squibb licences IONTAS’ mammalian display technology

IONTAS, a biotechnology company focused on antibody discovery technology development, has entered into a licensing agreement with Bristol Myers Squibb regarding its proprietary mammalian display. Under the terms of this agreement, IONTAS will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharma #Clinical trials #Covid-19 #Drug discovery #Therapeutics

Sitting down with…Biorelate

Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More

#Opinion